RxDoctor Payments Data

Crystal Mullins

Family · Carlsbad, NMNPI 1073983011

Payments from drug & device makers

$1,238in general payments, 2019–2025

Across 81 payments — averaging $15.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$338
  • AbbVie$320
  • Novo Nordisk$207
  • GSK$97
  • Lilly USA, LLC$69
  • Acella Pharmaceuticals, LLC$47
  • plus $159 from 8 others

What the payments were for

  • Food & beverage$1,238100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,238 in reported general payments places this provider in the 80th percentile of 1,080 family providers in New Mexico.

See all family providers in New Mexico

Medicare billing

Part B allowed, 2024
$64,752
Medicare patients
238
Services billed
1,796

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide30$29,288
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$20,133
MounjaroTirzepatide14$16,146
XareltoRivaroxaban14$15,007
MyrbetriqMirabegron23$13,646
OzempicSemaglutide13$12,013
TradjentaLinagliptin21$11,544
JanuviaSitagliptin Phosphate12$10,290
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$8,926
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$3,650
Gabapentin165$2,347
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$2,233
Levothyroxine Sodium281$1,723
Albuterol Sulfate HfaAlbuterol Sulfate63$1,472
Lisinopril219$1,281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$69$45,43444 claims
GSKTrelegy Ellipta$97$20,13323 claims
Novo NordiskOzempic$207$12,01313 claims
MerckJanuvia$15$10,29012 claims
Acella Pharmaceuticals, LLCNp Thyroid$47$74317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,080 family providers in New Mexico.

Other family in Carlsbad

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →